Omeros Corp. (3O8)
Munich
Closed
Oct 8, 2026
Day's Range
16.7552 wk Range
3.59Overview - 3O8 - Omeros Corp.
Key Statistics
Valuation
Enterprise Value
229.48M
P/E (Trailing)
‪-337.99‬
PEG Ratio
‪2.38‬
Price / Book
‪-23.73‬
EV / EBITDA
‪-0.96‬
Profitability
Gross Margin
‪97.20%‬
Return on Assets
‪-1.02%‬
Return on Equity
‪2.76%‬
Ownership
Shares Outstanding
72.08M
Price stats
50-Day Avg
‪14.18‬
200-Day Avg
‪11.14‬
Peers - 3O8 - Omeros Corp.
Peer Comparison
Compared with companies in Biotechnology listed on Munich.
- 3O8MunichOmeros Corp.+77.24%52-week change-338.00P/E (Trailing)—Profit Margin
- 0QFMunichModerna Inc.+87.60%52-week change25.19P/E (Trailing)‪-141.42%‬Profit Margin
- 0MEMunichTwist Bioscience Corporation+85.89%52-week change-126.15P/E (Trailing)‪50.72%‬Profit Margin
- 2LBMunichIovance Biotherapeutics Inc.+85.65%52-week change-11.96P/E (Trailing)‪34.27%‬Profit Margin
- B9B9P0MunichNovabay Pharmaceuticals Inc. R+80.00%52-week change-0.01P/E (Trailing)—Profit Margin
- 5JA1MunichSprint Bioscience AB+79.69%52-week change0.26P/E (Trailing)‪92.17%‬Profit Margin
- 42ZMunichRevolution Medicines, Inc.+78.79%52-week change-29.48P/E (Trailing)—Profit Margin
Profile Summary - 3O8 - Omeros Corp.
About
Omeros Corp. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. The company concentrates on immunologic and complement-mediated diseases, along with selected orphan and rare indications affecting inflammation, coagulopathies,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
